Kevin Outterson | Profiles RNS

Kevin Outterson, JD, LLM

Professor of Law and N. Neal Pike Scholar

Boston University School of Law

Dept of Health and Disability Law

LLM, University of Cambridge
JD, Northwestern University School of Law

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Associate Professor
Boston University School of Public Health
Health Law, Policy & Management

Executive Director
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

BU Sponsored Research

WT CARB-X PD Costs Cost-Share
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust

WT CARB-X Non Awardee Costs
04/01/2017 - 07/31/2021 (PI)
Wellcome Trust

CARB-X
08/01/2016 - 07/31/2021 (PI)
HHS/Assistant Secretary for Preparedness and Response
6 IDSEP160030-01-03

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen JA. Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. J Pharm Policy Pract. 2018; 11:8. PMID: 29632669.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar; 18(3):318-327. PMID: 29276051.

Theuretzbacher U, Savic M, Årdal C, Outterson K. Market watch: Innovation in the preclinical antibiotic pipeline. Nat Rev Drug Discov. 2017 Nov; 16(11):744-745. PMID: 28983100.

Barlam TF, Morgan JR, Kaplan WA, Outterson K, Pelton SI. Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. J Pediatric Infect Dis Soc. 2017 Sep 07.View Related Profiles.

Outterson, Kevin
Pelton, Stephen
Barlam, Tamar
Kaplan, Warren

PMID: 28992176.

Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, Findlay D. To the G20: incentivising antibacterial research and development. Lancet Infect Dis. 2017 Aug; 17(8):799-801. PMID: 28689703.

Deak D, Powers JH, Outterson K, Kesselheim AS. The Fight Against Multidrug-Resistant Bacteria. Ann Intern Med. 2017 01 03; 166(1):79. PMID: 28030672; DOI: 10.7326/L16-0582;.

Outterson K, McDonnell A. Antimicrobial Resistance: The Authors Reply. Health Aff (Millwood). 2016 10 01; 35(10):1936. PMID: 27702975.

Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov. 2016 09; 15(9):589-90. PMID: 27469032; DOI: 10.1038/nrd.2016.155;.

Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med. 2016 Jun; 13(6):e1002043. PMID: 27299990; PMCID: PMC4907461; DOI: 10.1371/journal.pmed.1002043;.

Deak D, Outterson K, Powers JH, Kesselheim AS. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration-Approved Antibiotics, 2010-2015. Ann Intern Med. 2016 Sep 06; 165(5):363-72. PMID: 27239977; DOI: 10.7326/M16-0291;.

Showing 10 of 38 results. Show More

Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016 May 01; 35(5):784-90. PMID: 27140983; DOI: 10.1377/hlthaff.2015.1139;.

Rex JH, Outterson K. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. Lancet Infect Dis. 2016 Apr; 16(4):500-5. PMID: 27036356; DOI: 10.1016/S1473-3099(15)00500-9;.

Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D, Daulaire N, Morel C, Rizvi Z, Balasegaram M, Dar OA, Heymann DL, Holmes AH, Moore LS, Laxminarayan R, Mendelson M, Røttingen JA. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016 Jan 16; 387(10015):296-307. PMID: 26603920; DOI: 10.1016/S0140-6736(15)00470-5;.

Outterson K, Powers JH, Daniel GW, McClellan MB. Repairing the broken market for antibiotic innovation. Health Aff (Millwood). 2015 Feb; 34(2):277-85. PMID: 25646108; DOI: 10.1377/hlthaff.2014.1003;.

Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A. An international legal framework to address antimicrobial resistance. Bull World Health Organ. 2015 Feb 01; 93(2):66. PMID: 25883395; PMCID: PMC4339972; DOI: 10.2471/BLT.15.152710;.

Hoffman SJ, Outterson K. What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43(2):363-8. PMID: 26242959; DOI: 10.1111/jlme.12253;.

Hoffman SJ, Outterson K. INTRODUCTION: What Will It Take to Address the Global Threat of Antibiotic Resistance? J Law Med Ethics. 2015; 43 Suppl 3:6-11. PMID: 26243236; DOI: 10.1111/jlme.12267;.

Outterson K. Clinical trial transparency--antidote to weaker off-label-promotion rules? N Engl J Med. 2014 Jul 3; 371(1):1-3. PMID: 24988551; DOI: 10.1056/NEJMp1402969;.

Outterson K. The Drug Quality and Security Act--mind the gaps. N Engl J Med. 2014 Jan 9; 370(2):97-9. PMID: 24369048; DOI: 10.1056/NEJMp1314691;.

Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics. 2013; 41(3):688-96. PMID: 24088160; DOI: 10.1111/jlme.12079;.

Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med. 2012 Nov 22; 367(21):1969-72. PMID: 23134357; DOI: 10.1056/NEJMp1212667;.

Outterson K. Punishing health care fraud--is the GSK settlement sufficient? N Engl J Med. 2012 Sep 20; 367(12):1082-5. PMID: 22970920.

Outterson K. Smoking and the First Amendment. N Engl J Med. 2011 Dec 22; 365(25):2351-3. PMID: 22149735; DOI: 10.1056/NEJMp1113011;.

Outterson K. Higher First Amendment hurdles for public health regulation. N Engl J Med. 2011 Aug 18; 365(7):e13. PMID: 21812665; DOI: 10.1056/NEJMp1107614;.

So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, Outterson K, Paccaud JP, Payne DJ, Peeling RW, Spigelman M, Weigelt J. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011 Apr; 14(2):88-94. PMID: 21439891; DOI: 10.1016/j.drup.2011.01.006;.

Kesselheim AS, Outterson K. Improving antibiotic markets for long-term sustainability. Yale J Health Policy Law Ethics. 2011; 11(1):101-67. PMID: 21381513.

Outterson K, Powers JH, Gould IM, Kesselheim AS. Questions about the 10 x ''20 Initiative. Clin Infect Dis. 2010 Sep 15; 51(6):751-2; author reply 754-5. PMID: 20731566; DOI: 10.1086/655955;.

Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010 Sep; 29(9):1689-96. PMID: 20820028; DOI: 10.1377/hlthaff.2009.0439;.

Outterson K, Kesselheim AS. How Medicare could get better prices on prescription drugs. Health Aff (Millwood). 2009 Sep-Oct; 28(5):w832-41. PMID: 19643778; DOI: 10.1377/hlthaff.28.5.w832;.

Outterson K. Foreword--Will HPV vaccines prevent cervical cancers among poor women of color?: global health policy at the intersection of human rights and intellectual property law. Am J Law Med. 2009; 35(2-3):247-52. PMID: 19697748.

Outterson K. Introduction: pharmaceutical innovation: law & the public''s health. J Law Med Ethics. 2009; 37(2):173-5. PMID: 19493064; DOI: 10.1111/j.1748-720X.2009.00363.x;.

Outterson K, Kesselheim AS. Market-based licensing for HPV vaccines in developing countries. Health Aff (Millwood). 2008 Jan-Feb; 27(1):130-9. PMID: 18180488; DOI: 10.1377/hlthaff.27.1.130;.

Outterson K. Should access to medicines and TRIPS flexibilities be limited to specific diseases? Am J Law Med. 2008; 34(2-3):279-301. PMID: 18697695.

Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007 Aug; 7(8):559-66. PMID: 17646029.

Outterson K. Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med. 2006; 32(2-3):159-73. PMID: 16927608.

Outterson K. Tragedy and remedy: reparations for disparities in black health. DePaul J Health Care Law. 2005; 9(1):735-91. PMID: 17061385.

Outterson K. Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics. 2005; 5(1):193-291. PMID: 15742578.

Outterson K, Butler JL. Disease management: legal strategies for the next generation of managed care. J Health Law. 1998; 31(3):291-314. PMID: 10620832.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 38 publications over 15 distinct years, with a maximum of 6 publications in 2016

Bar chart showing 38 publications over 15 distinct years, with a maximum of 6 publications in 2016

Year	Publications
1998	1
2005	2
2006	1
2007	1
2008	2
2009	3
2010	2
2011	4
2012	2
2013	2
2014	1
2015	5
2016	6
2017	5
2018	1

Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map

617.353.3103

Download vCard

Outterson's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (136) concept(s)

Co-Authors

See all (3) people

Similar People

See all (59) people